866-997-4948(US-Canada Toll Free)

Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Dec 2013

Category :

Oncology

No. of Pages : 81 Pages


Global Markets Directs, \'Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
  • A review of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Overview 7
Therapeutics Development 8
Pipeline Products for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Overview 8
Pipeline Products for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Comparative Analysis 9
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Therapeutics under Development by Companies 10
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Therapeutics under Investigation by Universities/Institutes 12
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Products under Development by Companies 16
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Products under Investigation by Universities/Institutes 17
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Companies Involved in Therapeutics Development 18
Amgen Inc. 18
Sanofi 19
Eli Lilly and Company 20
Novartis AG 21
Pfizer Inc. 22
Teva Pharmaceutical Industries Limited 23
AEterna Zentaris Inc. 24
Oncogenex Pharmaceuticals, Inc. 25
Dendreon Corporation 26
Debiopharm International S.A. 27
Cadila Pharmaceuticals Ltd. 28
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 34
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Assessment by Therapeutic Class 42
Drug Profiles 45
celecoxib - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
cabazitaxel - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
trebananib - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
icrucumab - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
apatorsen - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
CADI-05 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
lapuleucel-t - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
dovitinib lactate - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
dactolisib tosylate - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
PF-03446962 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
AEZS-108 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Mixed Bacterial Vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
CEP-11981 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Debio-1141 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Recent Pipeline Updates 68
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Dormant Projects 77
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Product Development Milestones 78
Featured News & Press Releases 78
May 07, 2013: Exelixis To Feature Nine Presentations On Cabozantinib At 2013 ASCO Annual Meeting 78

Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 81
Disclaimer 81

List of Table


Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), H2 2013 8
Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Number of Products under Investigation by Universities/Institutes, H2 2013 12
Comparative Analysis by Late Stage Development, H2 2013 13
Comparative Analysis by Clinical Stage Development, H2 2013 14
Comparative Analysis by Early Stage Development, H2 2013 15
Products under Development by Companies, H2 2013 16
Products under Investigation by Universities/Institutes, H2 2013 17
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Amgen Inc., H2 2013 18
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Sanofi, H2 2013 19
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Eli Lilly and Company, H2 2013 20
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Novartis AG, H2 2013 21
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Pfizer Inc., H2 2013 22
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2013 23
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by AEterna Zentaris Inc., H2 2013 24
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2013 25
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Dendreon Corporation, H2 2013 26
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Debiopharm International S.A., H2 2013 27
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Cadila Pharmaceuticals Ltd., H2 2013 28
Assessment by Monotherapy Products, H2 2013 29
Number of Products by Stage and Target, H2 2013 32
Number of Products by Stage and Mechanism of Action, H2 2013 36
Number of Products by Stage and Route of Administration, H2 2013 39
Number of Products by Stage and Molecule Type, H2 2013 41
Number of Products by Stage and Therapeutic Class, H2 2013 44
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Therapeutics - Recent Pipeline Updates, H2 2013 68
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Dormant Projects, H2 2013 77

List of Chart


Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), H2 2013 8
Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 10
Number of Products under Investigation by Universities/Institutes, H2 2013 12
Comparative Analysis by Clinical Stage Development, H2 2013 14
Assessment by Monotherapy Products, H2 2013 29
Number of Products by Top 10 Target, H2 2013 30
Number of Products by Stage and Top 10 Target, H2 2013 31
Number of Products by Top 10 Mechanism of Action, H2 2013 34
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 35
Number of Products by Top 10 Route of Administration, H2 2013 38
Number of Products by Stage and Top 10 Route of Administration, H2 2013 39
Number of Products by Top 10 Molecule Type, H2 2013 40
Number of Products by Stage and Top 10 Molecule Type, H2 2013 41
Number of Products by Top 10 Therapeutic Class, H2 2013 42
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 43

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *